Literatur
-
1
Cochrane Injuries Group Albumin Reviewers .
Human albumin administration in critically ill patients: systematic review of randomised controlled trials.
BMJ.
1998;
317
235-240
-
2
Coronel B, Mercatello A, Martin X, Lefrancois N.
Hydroxyethylstarch and renal function in kidney transplant recipients.
Lancet.
1997;
349
884
-
3
Deman A, Peeters P, Sennesael J.
Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis.
Nephrol Dial Transplant.
1999;
14
1517-1520
-
4
Legendre C, Thervet E, Page B, Percheron A, Noel L H, Kreis H.
Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation.
Lancet.
1993;
342
248-249
-
5
Mailloux L, Swartz C D, Capizzi R, Kim K E, Onesti G, Ramirez O. et al .
Acute renal failure after administration of low-molecular weight dextran.
N Engl J Med.
1967;
277
1113-1118
-
6
Moran M, Kapsner C.
Acute renal failure associated with elevated plasma oncotic pressure.
N Engl J Med.
1987;
317
150-153
-
7
Nearman H S, Herman M L.
Toxic effects of colloids in the intensive care unit.
Crit Care Clin.
1991;
7
713-723
-
8
Ragaller M J, Theilen H, Koch T.
Volume replacement in critically ill patients with acute renal failure.
J Am Soc Nephrol.
2001;
12
S33-39
(Suppl 17)
-
9
Treib J, Baron J F, Grauer M T, Strauss R G.
An international view of hydroxyethyl starches.
Intensive Care Med.
1999;
25
258-268
-
10
Vermeulen L C, Ratko T A, Erstad B L, Brecher M E, Matuszewski K A.
A paradigm for consensus: The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions.
Arch Intern Med.
1995;
155
373-379
PD Dr. med. D. M. Alscher
Abteilung für Allgemeine Innere Medizin und Nephrologie
Robert-Bosch Krankenhaus
Auerbachstr. 110
70376 Stuttgart
eMail: dominik.alscher@rbk.de
